Imidafenacin on bladder and cognitive function in neurologic OAB patients
详细信息 查看全文
- 作者：Ryuji Sakakibara (1)
Fuyuki Tateno (1)
Masashi Yano (2)
Osamu Takahashi (3)
Megumi Sugiyama (3)
Takeshi Ogata (1)
Hiroyuki Haruta (1)
Masahiko Kishi (1)
Yohei Tsuyusaki (1)
Tatsuya Yamamoto (4)
Tomoyuki Uchiyama (5)
Tomonori Yamanishi (5)
Chiharu Yamaguchi (5) - 关键词：Imidafenacin ; Overactive bladder ; Cognitive function ; Prefrontal cortex ; Near ; infrared spectroscopy (NIRS)
- 刊名：Clinical Autonomic Research
- 出版年：2013
- 出版时间：August 2013
- 年：2013
- 卷：23
- 期：4
- 页码：189-195
- 全文大小：409KB
- 参考文献：1. Abram P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology lower urinary tract function: report from the Standardisation Subcommittee of International Continence Society. Neurourol Urodyn 21:167-78 CrossRef
2. Robinson D, Cardozo L (2012) Overactive bladder: diagnosis and management. Maturitas 71:188-93 CrossRef
3. Homma Y, Yamaguchi O, Hayashi K, Neurogenic Bladder Society Committee (2005) An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 96:1314-318 CrossRef
4. Fowler CJ, Griffiths D, de Groat WC (2008) The neural control of micturition. Nat Rev Neurosci 9:453-66 CrossRef
5. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M (2008) Dementia and lower urinary dysfunction: with a reference to anticholinergic use in elderly population. Int J Urol 15:778-88 CrossRef
6. Chancellor M, Boone T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167-74 CrossRef
7. Kobayashi F, Yageta Y, Yamazaki T, Wakabayashi E, Inoue M, Segawa M, Matsuzawa S (2007) Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task. Arzneimittelforschung 57:147-54
8. Yamada S, Seki M, Ogoda M, Fukata A, Nakamura M, Ito Y (2011) Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder. J Pharmacol Exp Ther 336:365-71 CrossRef
9. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, Hattori T (2001) Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci Basic Clin 92:76-5 CrossRef
10. Folstein M, Folstein S, McHugh PR (1975) Mini-mental state; a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-98 CrossRef
11. Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatr 141:1356-364
12. Dubois B, Slachevsky A, Litvan I, Pillon B, The FAB (2000) A frontal assessment battery at bedside. Neurology 55:1621-626 CrossRef
13. Perneczky R, Wagenpfeil S, Komossa K, Grimmer T, Diehl J, Kurz A (2006) Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry 14:139-44 CrossRef
14. Laks J, Baptista EMR, Contino ALB, de Paula EO, Engelhardt E (2007) Mini-Mental State Examination norms in a community-dwelling sample of elderly with low schooling in Brazil. Cad Saúde Pública Rio de Janeiro 23:315-19 CrossRef
15. Salmon DP, Bondi MW (2009) Neuropsychological assessment of dementia. Annu Rev Psychol 60:257-82 CrossRef
16. Sakakibara R, Tsunoyama K, Takahashi O, Sugiyama M, Kishi M, Ogawa E, Uchiyama T, Yamamoto T, Yamanishi T, Awa Y, Yamaguchi C (2010) Real-time measurement of oxyhemoglobin concentration changes in the frontal micturition area: an fNIRS study. Neurourol Urodyn 29:757-64 CrossRef
17. Strangman G, Boas DA, Sutton JP (2002) Non-invasive neuroimaging using near-infrared light. Biol Psychiatry 52:679-93 CrossRef
18. Griffiths D, Tadic SD, Schaefer W, Resnick NM (2007) Cerebral control of the bladder in normal and urge-incontinent women. NeuroImage 37:1- CrossRef
19. Kitagawa Y, Kuribayashi M, Narimoto K, Kawaguchi S, Yaegashi H, Namiki M (2011) Immediate effect on overactive bladder symptoms following administration of imidafenacin. Urol Int 86:330-33 CrossRef
20. Homma Y, Yamaguchi O (2009) Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol 16:499-06 CrossRef
21. Zaitsu M, Mikami K, Ishida N, Takeuchi T (2011) Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST Study). Adv Urol; 854697. Epub 2011 Oct 20
22. Yokoyama T, Koide T, Hara R, Fukumoto K, Miyaji Y, Nagai A (2012) Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study. Urol Int. [Epub ahead of print]
23. Wada N, Watanabe M, Kita M, Matsumoto S, Osanai H, Yamaguchi S, Numata A, Fujisawa M, Saga Y, Hou K, Iuchi H, Niibori D, Kura T, Taniguchi A, Kunieda M, Nakata Y, Kakizaki H (2012) Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. Urol Int 89:215-21 CrossRef
24. Donnellan CA, Fook L, McDonald P, Playfer JR (1997) Oxybutynin and cognitive dysfunction. BMJ 315:1363-364 CrossRef - 作者单位：Ryuji Sakakibara (1)
Fuyuki Tateno (1)
Masashi Yano (2)
Osamu Takahashi (3)
Megumi Sugiyama (3)
Takeshi Ogata (1)
Hiroyuki Haruta (1)
Masahiko Kishi (1)
Yohei Tsuyusaki (1)
Tatsuya Yamamoto (4)
Tomoyuki Uchiyama (5)
Tomonori Yamanishi (5)
Chiharu Yamaguchi (5)
1. Department of Neurology and Internal Medicine, Sakura Medical Center, Toho University, 564-1 Shimoshizu, Sakura, 285-8741, Japan
2. Department of Urology, Sakura Medical Center, Toho University, Sakura, Japan
3. Clinical Physiology Unit, Sakura Medical Center, Toho University, Sakura, Japan
4. Department of Neurology, Chiba University, Chiba, Japan
5. Continence Center, Dokkyo Medical College, Tochigi, Japan
文摘
Objective To explore imidafenacin’s effects on bladder and cognitive function in neurologic overactive bladder (OAB) patients. Methods Sixty-two subjects (25 men, 37 women; mean age 70?years (25-6) with OAB due to neurologic diseases) were enrolled in the study. We conducted a urinary symptom survey and cognitive tests (MMSE, FAB, ADAS-cog) in all patients. We performed urodynamics in 35 patients and measured real-time near-infrared spectroscopy (NIRS)-urodynamics in eight patients before and after the administration of imidafenacin, an anticholinergic agent, for 3?months at 0.2?mg/day. Results Imidafenacin significantly ameliorated urinary urgency, nighttime urinary frequency, and quality of life index (p?<?0.05). Three cognitive measures did not change significantly. Urodynamics showed increased bladder capacity (p?<?0.05) but detrusor overactivity did not change significantly. NIRS showed that the subtraction of oxyhemoglobin between the start of filling and the first sensation increased in the bilateral prefrontal area but without statistical significance. Conclusions Imidafenacin ameliorated bladder sensation without cognitive worsening, with a trend of prefrontal activation. Regarding cognitive function, imidafenacin is safely used in OAB patients due to neurologic diseases. Synopsis In order to explore imidafenacin (anticholinergic agent)’s effects on bladder and brain function, we performed urinary questionnaire, cognitive tests, urodynamics and near-infrared spectroscopy (selected cases) in 62 overactive bladder (OAB) patients due to various neurologic diseases. As a result, imidafenacin ameliorated bladder sensation without cognitive worsening, with a trend of prefrontal activation. Imidafenacin seems safe in treating OAB patients due to neurologic diseases.